| INTRODUCTION
Treat-to-target is a recommended and widely accepted management strategy for rheumatoid arthritis (RA), which aims to achieve remission or a low disease activity. Disease activity is evaluated by some composite measures, including the patient's and physician's global assessments, swollen joint counts (SJCs) or tender joint counts (TJCs) and the Creactive protein (CRP) level (Smolen et al., 2016) . The patient's global assessment (PGA), which is a patient-reported satisfaction scale and one of the components of several composite measures, is often the limiting factor for achieving remission because it is often only the PGA that does not meet the remission criteria, whereas the other components do meet the criteria ). Yet, it remains unclear which factors of a clinical assessment contribute to an increased PGA score when the TJC and CRP level meet the Boolean remission criteria (Felson et al., 2011) . Some studies have reported factors that affect the PGA score-for example, the patient's visual analogue scale score for pain, health assessment questionnaire (HAQ) score (Studenic, Radner, Smolen, & Aletaha, 2012; Lindström Egholm et al., 2015; Markenson et al., 2012) and Steinbrocker class (Furu et al., 2014) . Wechalekar et al. (2012) reported that 25-36% of patients in remission according to the Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) had foot disease activity, and foot disease activity predicted transition from remission to relapse by up to twofold. Evaluation of foot disease activity is important; however, it is unclear how foot disease activity affects the PGA.
We hypothesized that foot disease activity would contribute to an increased PGA among patients with RA whose TJCs and SJCs and CRP level (mg/dl) met the Boolean remission criteria.
The purpose of the present study was to examine how much some factors, including foot disease activity, affect the elevation of PGA among these patients.
| MATERIALS AND METHODS
We conducted a retrospective cross-sectional study using the National Database of Rheumatic Diseases by iR-net (Division of Rheumatology, Immunologic Disorder Network, National Hospital Organization) in Japan (NinJa). Data collection began in 2002 and was updated annually according to the data distribution of the participating researchers. At the end of March 2017, 51 institutions in Japan were participating in NinJa (Matsui et al., 2007) . The NinJa project was reviewed and approved by the Sagamihara National Hospital's 
| RESULTS
Of 15,341 patients with RA in the NinJa database, we included 8,795
patients whose CRP level was ≤1.0 mg/dl and both SJCs and TJCs were ≤1. Of these, 6,946 (79.0%) patients were women. Patients' median age was 67 years (interquartile range: 57-74 years), with a median disease duration of 9 years (interquartile range: 5-12 years).
Either swelling or tenderness of the foot joints, which were not included in the 28 joints of the Boolean criteria (foot disease activity), were observed in 845 patients (9.6%). Characteristics dichotomized by the PGA ≤1 (4,698 patients [53.4%]) and PGA >1 (4,097 [46.6%]) are shown in Table 1. A total of 2,021 patients were missing the disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR). Overall, 6,495 of 6,774 patients (95.9%) were in DAS 28-ESR remission (<2.6), and 500 (7.7%) with DAS28-ESR remission had foot disease activity.
Logistic regression analysis showed that age, the Steinbrocker stage, mHAQ score, HADS-A score, HADS-D score and foot disease activity were factors associated with an increased PGA score. All the variance inflation factor values were <2, indicating that there was no apparent multicollinearity (Table 2) . Regarding the accuracy of foot disease activity contributing to an increased PGA score, the sensitivity was 14.9% (607/4,097), specificity was 94.9% (4,460/4,698), positive likelihood ratio was 2.92 and negative likelihood ratio was 0.9.
| DISCUSSION
Naniwa and colleagues reported that 27% of 177 patients with RA who were in remission according to the American College of Rheumatology/European League Against Rheumatism definitions had foot disease activity; however, there was no significant difference in the PGA (Naniwa, Iwagaitsu, Tamechika, Maeda, & Niimi, 2016) . Our study demonstrated that positive foot disease activity was associated with a worse PGA. This discrepancy may have been because the previous study investigated patients who achieved remission criteria; conversely, our study included patients who met the near-remission criteria. Consequently, the PGA score was more wide-ranging in our study. Bakker et al. (2012) reported that the DAS28 underestimated the actual disease activity and expected joint damage of individual patients with early RA predominantly with disease in the feet. Our study's findings emphasized the importance of foot disease activity, especially in patients whose PGA score was high, although the other components of the composite measure were low. Evaluators might not always perform an examination of the feet, but this assessment is important in managing patients with RA, whether or not they are in remission, based on some composite measures.
Our study had a couple limitations. First, the retrospective nature of the study design limited the clinical interpretation of the study results. A further prospective observation study is needed to clarify the association between foot disease activity and PGA. Second, our study may not have had sufficient data on foot disease activity. Several studies have reported that 20-40% of patients with DAS28
remission have foot disease activity (Son, Song, Lim, Seo, & Kim, 2012; van der Leeden, Steultjens, van Schaardenburg, & Dekker, 2010 ). Yet, in the database used in our study, 7.7% of patients with DAS28-ESR remission had foot disease activity. The ratio was lower than that found in other studies; thus, it may be inadequate for assessing foot disease activity. If this is the case, then there is a reasonable association between foot disease activity and PGA.
| CONCLUSIONS
Foot disease activity affects Boolean remission in Japanese patients with RA. Foot disease activity, and the mHAQ score, HADS-A score and HADS-D score contribute to increasing only the PGA score in patients who meet the Boolean remission criteria, with the exception of the PGA. Further studies are needed to assess the association between foot disease activity and PGA. If the efficacy of foot disease activity is validated as a factor that increases the PGA score, it may be valuable for physicians to assess the foot disease activity only when the PGA score is high.
